CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a post-hoc win odds analysis of all-cause mortality and hospitalization from the Phase 3 INNO2VATE trials of vadadustat at the American Society of Nephrology Kidney Week 2025 (ASN Kidney Week). The presentation entitled, “Win-Odds Analysis of Deaths and Hospitalization in Patie ...

Core Insights - Akebia Therapeutics and Innovative Renal Care announced the broad availability of Vafseo (vadadustat) for treating anemia due to chronic kidney disease (CKD) in dialysis patients across all IRC clinics [1][2] - Vafseo was approved by the FDA in March 2024 and became commercially available in January 2025, targeting adults on dialysis for at least three months [3] Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [6] - Innovative Renal Care is a national leader in kidney care, operating over 230 dialysis centers across 28 states and Washington, D.C., emphasizing patient-centered care and partnerships with nephrologists [5] Product Details - Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates the production of erythropoietin, thereby increasing hemoglobin and red blood cell production to manage anemia [7] - The drug is indicated for adults with anemia due to CKD who have been on dialysis for at least three months and is approved for use in 37 countries [8] Market Impact - Vafseo is now accessible to over 55,000 patients through IRC's dialysis provider protocols, with expectations to expand access to more than 275,000 patients by the end of Q4 2025 [4]